Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway
Frontiers in Endocrinology · 18.08.2026 · 17
DOI: 10.3389/fendo.2026.1903580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 18.08.2026. Verfasst von Xiaoying Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Glucosides, NF-kappa B, Muscle Fibers, Skeletal, Glycation End Products, Advanced. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Empagliflozin is an established sodium-glucose cotransporter 2 inhibitor with reported anti-inflammatory activity, but its effects on advanced glycation end product/high-glucose-induced inflammatory injury in skeletal muscle cells remain unclear.
Methods
A GEO-derived transcriptomic dataset from gastrocnemius muscle of type 2 diabetes mellitus rats was analyzed to screen pathways associated with diabetes-related skeletal muscle injury, and molecular docking was performed to explore the possible structural compatibility between empagliflozin and RAGE. Differentiated C2C12 myotubes were exposed to AGE-BSA under high-glucose conditions and treated with empagliflozin. Cell viability was assessed using CCK-8, and RAGE, NF-κB, IL-6, and TNF-α were evaluated by qRT-PCR, Western blotting, immunofluorescence, and ELISA.
Results
Bioinformatic enrichment highlighted AGE-RAGE signaling and inflammation-related NF-κB pathways in diabetic skeletal muscle. Molecular docking provided a computational structural hypothesis suggesting possible compatibility between empagliflozin and human RAGE involving Asp160. In AGE-BSA/high-glucose-stimulated C2C12 myotubes, empagliflozin improved cell viability and was accompanied by reduced RAGE expression, lower NF-κB phosphorylation and immunofluorescence-based nuclear accumulation, and lower IL-6 and TNF-α expression and secretion.
Discussion
Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammatory injury in C2C12 myotubes, and this effect is associated with reduced activation of RAGE/NF-κB-related inflammatory signaling. Further gain- or loss-of-function experiments and validation in diabetic animal models are required to determine whether this pathway is causally involved and whether the observed cell-based effect can be translated into an in vivo setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China.
Zitieren
APA
Zhang, X., Mao, Y., Wu, J., Deng, X., Wang, H., & Kang, Z. (2026). Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.1903580
Vancouver
Zhang X, Mao Y, Wu J, Deng X, Wang H, Kang Z. Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1903580
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoying and Mao, Yu and Wu, Jiaxing and Deng, Xinyu and Wang, Huanhuan and Kang, Zhiqiang},
title = {Empagliflozin attenuates AGE-BSA/high-glucose-induced inflammation in C2C12 myotubes associated with suppression of the RAGE/NF-κB pathway},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.1903580}
}
EUVIMED